CDER Oncology Division Handling Most Cancer Prevention Drugs Ahead Of Reorg
This article was originally published in The Pink Sheet Daily
Executive Summary
Two approved products – Pfizer’s Celebrex and Axcan’s Photofrin – and 69 INDs were transferred to the Division of Oncology Drug Products, ahead of the creation of an Office of Oncology Drug Products. The transfer excludes biologics and those drugs aimed at reducing the risk of non-melanoma skin cancer.